Celcuity's Upcoming Presentation at ESMO Congress
Celcuity Inc., a pioneer in oncology therapies, has made headlines with the announcement that clinical findings from its Phase 3 VIKTORIA-1 trial will be presented at a notable oncology event. As a clinical-stage biotechnology company, Celcuity is dedicated to advancing targeted treatments for various forms of cancer.
Insights into the VIKTORIA-1 Trial
At this prestigious gathering, Celcuity will unveil the results derived from the PIK3CA wild-type patient cohort of the VIKTORIA-1 trial. With a focus on the role of gedatolisib combined with fulvestrant, this trial emphasizes advanced therapies for patients suffering from HR+/HER2- advanced breast cancer.
Late Breaking Presentation Details
The late-breaking presentation will offer a thorough analysis of the efficacy and safety profiles documented in the trial, which evaluated gedatolisib—an innovative pan-PI3K and mTORC1/2 inhibitor. The session will take place on October 18, 2025, during the Proffered Paper Session focused on metastatic breast cancer and is expected to garner significant attention from the oncology community.
Key Presentation Highlights
The presentation, titled "Gedatolisib + Fulvestrant ± Palbociclib vs Fulvestrant in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer: First Results from VIKTORIA-1," will provide crucial insights into the promising treatment strategies being developed by Celcuity. With abstract number 3535 assigned to this work, it is anticipated to be a focal point at the congress.
About Celcuity Inc.
Celcuity Inc. is making remarkable strides in the field of oncology with its dedicated research on targeted therapies. The company's core efforts emphasize the development of gedatolisib, which aims to disrupt the PAM pathway and provide effective solutions for various solid tumors. Currently undergoing extensive clinical testing, the VIKTORIA-1 trial has completed enrollment for its PIK3CA wild-type cohort, yielding promising topline data.
Future Directions in Cancer Treatment
In addition to the VIKTORIA-1 trial, Celcuity is progressing with a second pivotal study, known as VIKTORIA-2, which will assess gedatolisib paired with a CDK4/6 inhibitor as a first-line option for treating HR+/HER2- advanced breast cancer. This future-focused research promises a wealth of opportunities to further enhance treatment efficacy in combating aggressive cancer types.
Engagement with the Scientific Community
Through its participation in key events like the ESMO Congress, Celcuity demonstrates its commitment to collaborating with peers, sharing crucial findings, and actively contributing to the body of knowledge surrounding cancer treatments. The exchange of insights at such conferences plays a pivotal role in advancing the field and improving patient outcomes.
Frequently Asked Questions
What is the VIKTORIA-1 trial?
The VIKTORIA-1 trial is a Phase 3 clinical trial evaluating the combination of gedatolisib and fulvestrant for patients with HR+/HER2- advanced breast cancer.
When will the presentation occur?
The oral presentation showcasing results from the trial is scheduled for October 18, 2025, at the European Society for Medical Oncology (ESMO) Congress.
What is gedatolisib?
Gedatolisib is a novel therapy that inhibits both the PI3K and mTOR pathways, targeting the underlying mechanisms of cancer progression.
How can I learn more about Celcuity?
Further information about Celcuity and its clinical trials can be found on their official website.
Who should attend the ESMO Congress?
The ESMO Congress is aimed at healthcare professionals, researchers, and stakeholders involved in oncology treatment and research, providing a platform for the exchange of knowledge.